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Abstract
Background: A recent systematic review identified four candidate serum-soluble bone-turnover biomarkers
(dickkopf-1, Dkk-1; macrophage-colony stimulating factor, M-CSF; matrix metalloproteinase-3, MMP-3;
osteoprotegerin, OPG) showing possible association with psoriatic arthritis (PsA). We aimed to: (i) confirm and
determine if these four biomarkers are associated with PsA; (ii) differentiate psoriasis cases with and without
arthritis; and (iii) differentiate PsA cases with and without axial arthritis.
Methods: A prospective cross-sectional comparative two-centre study recruited 200 patients with psoriasis without
arthritis (PsC), 127 with PsA without axial arthritis (pPsA), 117 with PsA with axial arthritis (psoriatic spondyloarthritis,
PsSpA), 157 with ankylosing spondylitis (AS) without psoriasis, and 50 matched healthy controls (HC). Serum
biomarker concentrations were measured using ELISA. Multivariable regression and receiver operating characteristic
analyses were performed.
Results: MMP-3 concentrations were significantly higher and M-CSF significantly lower in each arthritis disease group
compared with HC (p≤ 0.02). MMP-3 concentrations were significantly higher (adjusted odds ratio, ORadj 1.02 per ng/ml
increase in concentration; p = 0.0004) and M-CSF significantly lower (ORadj 0.44 per ng/ml increase; p = 0.01) in PsA
(pPsA and PsSpA combined) compared with PsC. Dkk-1 concentrations were significantly higher (ORadj 1.22 per ng/mL
increase; p = 0.01), and OPG concentrations significantly lower (ORadj 0.20 per ng/mL increase; p = 0.02) in patients with
axial arthritis (PsSpA and AS combined) than in those without (pPsA). Furthermore, Dkk-1 concentrations were
significantly higher along a spectrum of increasing axial arthritis; Dkk-1 concentrations were higher in AS compared with
PsSpA (ORadj 1.18 per ng/mL increase; p = 0.02). Receiver operating characteristic analysis showed MMP-3 to be the best
single biomarker for differentiating PsA from PsC (AUC 0.70 for a cut-off of 14.51 ng/mL; sensitivity 0.76, specificity 0.60).
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Conclusions: MMP-3 and M-CSF are biomarkers for the presence of arthritis in psoriatic disease, and could therefore be
used to screen for PsA in psoriasis cohorts. Dkk-1 and OPG are biomarkers of axial arthritis; they could therefore be used
to screen for the presence of axial disease in PsA cases, and help differentiate PsSpA from AS. High concentrations of
Dkk-1 in AS and PsSpA compared with HC, support previous reports that Dkk-1 is dysfunctional in the
spondyloarthritides.
Keywords: Biomarkers, Psoriatic arthritis, Ankylosing spondylitis, Psoriasis, Spondylitis, Dkk-1, MMP-3, M-CSF,
Osteoprotegerin
Background
Psoriatic arthritis (PsA) and ankylosing spondylitis
(AS) are chronic inflammatory conditions of the mus-
culoskeletal system belonging to the family of spondy-
loarthritis (SpA). They are characterised by bone
resorption in the form of erosion and osteolysis, and
new bone formation (osteoproliferation) in the form of
syndesmophytes, periostitis and sacroiliac joint (SIJ)
ankylosis. The bone forming and resorbing phenotypes
of PsA and AS make them good candidates to investi-
gate the role of serum-soluble bone-turnover
biomarkers.
A systematic literature review of serum-soluble bone
and cartilage-turnover markers in PsA and psoriatic
spondyloarthritis (PsSpA) [1], identified four candidate
bone-turnover markers in PsA: dickkopf 1 (Dkk-1),
which inhibits Wnt-mediated bone formation; osteo-
protegerin (OPG), which inhibits RANK-mediated
bone resorption; macrophage colony stimulating factor
(M-CSF),which promotes bone resorption; and matrix
metalloproteinase 3 (MMP-3), which degrades the
extra-cellular matrix of bone and cartilage, leading to
bone erosion and joint space narrowing.
We have previously reported that the presence of
psoriasis and HLA-B27 are important factors that de-
fine the pattern of axial disease in SpA [2]. We now
hypothesise that serum-soluble bone-turnover
biomarkers are associated with disease phenotype and
disease severity in patients with SpA. Using the same
cohort and comparator samples from patients with
psoriasis only (cases) and matched healthy controls,
the aims of this study were to confirm and determine
if these four biomarkers (Dkk-1, M-CSF, MMP-3, and
OPG): (i) are associated with PsA; (ii) differentiate pa-
tients with psoriasis with and without arthritis; and




A prospective cross-sectional comparative two-centre
study (Axial Disease in Psoriatic Arthritis study;
ADIPSA) was performed, recruiting unselected
consecutive patients with PsA and AS from a
secondary-care teaching hospital attended by approxi-
mately 600 patients with PsA and 700 with AS between
August 2012 and October 2013. The study inclusion
criteria were: patients aged ≥ 18 years with either PsA
fulfilling the Classification of Psoriatic Arthritis (CAS-
PAR) criteria [3, 4] or AS fulfilling the 1987 modified
New York diagnostic criteria (mNYc) for AS [5]. The
enrolled patients with PsA and AS were reclassified as:
peripheral-only PsA (pPsA) without radiographic axial
disease (RAD), PsA with RAD (psoriatic spondyloar-
thritis; PsSpA), and AS without psoriasis (AS). In keep-
ing with previous publications [6, 7], inflammatory
RAD was defined in patients with PsSpA as the pres-
ence of: New York criteria sacroiliitis (unilateral
grade ≥ 3, or bilateral grade ≥ 2 sacroiliitis), and/or ≥ 1
marginal/paramarginal syndesmophyte(s) of the cer-
vical or lumbar spine. The most recent (≤10 years)
axial radiographs of all participants with SpA were
scored using two validated indices: the Psoriatic Arth-
ritis Spondylitis Radiology Index (PASRI) [8] and the
modified Stoke Ankylosing Spondylitis Spinal Score
(mSASSS) [9].
At the time of blood sample collection all study partic-
ipants were assessed by a rheumatologist (DRJ) who col-
lected data on patient-reported outcome measures
(PROMs), clinical examination indices, and axial radio-
graphic indices. Further details on the ADIPSA cohort
have been published previously [2].
Serum from 200 patients with purely cutaneous psor-
iasis (PsC) without clinical evidence of joint problems
for ≥ 10 years since the diagnosis of psoriasis, assessed
by a dermatologist, were provided from the Depart-
ment of Dermatology (University of Michigan), for
whom associated clinical details including sex, age, dis-
ease duration, biologic and synthetic disease-modifying
anti-rheumatic drug (DMARD) use, and Psoriasis Area
Severity Index (PASI) were available. Serum from 50
healthy controls (HC) was obtained from the UK
Health and Social Care Information Centre (HSIC), the
controls having been deemed healthy using a screening
questionnaire. HCs were age, sex and ethnicity
matched to the enrolled patients with PsA.
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Serum biomarker testing
Patients provided non-fasted blood samples on the
morning of clinical assessment and serum was stored at
− 80 °C, with minimal freeze-thaw cycles [10]. Commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kits were used to measure biomarker concentra-
tions in each subject group in duplicate. Quantikine
ELISA kits (R&D systems, UK) were used to measure
total Dkk-1 (functionally active and inactive Dkk-1), total
MMP-3 (pro-MMP-3 and active-MMP-3), and total M-
CSF. Another ELISA kit (Biorbyte, UK) was used to
measure total OPG. A percentage coefficient of variation
(CV%) ≤ 15% between duplicate samples was considered
acceptable, and samples were re-tested until CV% ≤ 15%
was attained.
Statistical analysis
A statistical analysis plan was decided a priori, guided by
the systematic review of biomarkers [1] and mechanistic
hypotheses. Adjustment for multiple testing was there-
fore not required. Data were analysed using STATA12.1
(2011 TX, USA). Since serum biomarker concentrations
were not normally distributed (skewed to the right, at
group and cohort level), a logarithmic transformation
was applied prior to all analyses. Reverse, stepwise, logis-
tic regression, adjusted for covariables at blood sampling
(sex, age, disease duration from diagnosis, anti-TNF use,
body mass index (BMI), AS Disease Activity Score
(ASDAS), and PASI) was used to compare biomarker
concentrations between subject groups. The alpha level
for statistical significance was 0.05.
Results
The study enrolled 651 subjects: 200 with PsA, 201
with AS, 200 with PsC and 50 HC. The PsA and AS
cases were reclassified as: 127 pPsA, 117 PsSpA, and
157 AS (43 cases of psoriasis, but meeting both modi-
fied New York criteria for AS and CASPAR criteria for
PsA, were reclassified as PsSpA for this research
study). The clinical characteristics of the groups are
detailed in Table 1. Axial radiographs were mostly re-
cent (median interval between radiographs being per-
formed and study enrolment 2.4 years, IQR 1.4, 4.1).
Excellent inter-rater (intraclass correlation coefficient
(ICC) ≥ 0.85) and intra-rater (ICC ≥ 0.88) reliability was
achieved by raters for the PASRI, mSASSS and regional
subdomains. For brevity, further clinical, radiographic
and treatment characteristics of this cohort are de-
scribed in the clinical-radiographic paper on the
ADIPSA cohort [2].
Assay reliability
Each of the four biomarkers achieved an acceptable
inter-assay CV% (≤15%). However, despite several runs,
48 of 651 duplicate OPG samples did not attain an ac-
ceptable intra-assay CV% ≤ 10, and were excluded from
subsequent analyses (14/157 AS, 1/118 PsSpA, 19/127
pPsA, 6/200 PsC, 9/50 HC).
Biomarker concentrations in the cohort and analysis of
covariables
Serum biomarker concentrations are detailed in Table 2.
Linear and logistic regression were used to determine if
biomarker concentrations were affected by the following
covariables at blood sampling: sex, age, disease duration,
anti-TNF use, BMI, HLA-B27 positivity, high-sensitivity
C-reactive protein (hsCRP), and ASDAS. The covariables
included in the final regression models are given in
Table 2. MMP-3 (regression coefficient, ß 0.01; p = 0.04)
and OPG (ß 0.01; p < 0.0001) concentrations significantly
increased with age.
Table 1 Demographic and clinical characteristics of the healthy control and disease groups
At blood sampling HC (n = 50) PsC (n = 200) pPsA (n = 127) PsSpA (n = 117) AS (n = 157)
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age (years) 59.93 (51.44, 67.56) 54 (42, 65) 58.45 (50.31, 66.63) 59.53 (59.56, 66.54) 54.70 (44.52, 63.41)
Disease duration (years) n/a 24 (16, 36.5) 15 (7, 26) 18 (9, 27) 22 (10, 31)
BMI (kg/m2) n/a n/a 29.04 (26.30, 32.84) 28.56 (26.06, 31.98) 27.07 (24.58, 30.13)
CRP (mg/dL) n/a n/a 2 (0, 5) 3 (2, 7) 4 (1, 10)
ASDAS (units) n/a n/a 2.1 (1.3, 2.7) 2.2 (1.5, 2.9) 2.1 (1.6, 2.9)
PASI (units) n/a 4.8 (2.4, 8.8) 0.8 (0.0, 2.6) 0.8 (0.0, 2.8) n/a
n (%) n (%) n (%) n (%) n (%)
Male sex 26 (52.00) 102 (51.00) 66 (51.97) 74 (63.25) 118 (75.16)
Anti-TNF use n/a 26 (13.00) 47 (37.01) 53 (45.30) 59 (37.58)
HLA-B27 positive n/a n/a 9 (7.09) 47 (40.17) 140 (89.17)
HC healthy control, PsC psoriasis without arthritis, pPsA peripheral PsA, PsSpA psoriatic spondyloarthropathy, AS ankylosing spondylitis, IQR interquartile range, n number/
proportion, n/a not available/applicable, BMI body mass index, CRP C-reactive protein, ASDAS AS Disease Activity Score, PASI Psoriasis Area Severity Index,
HLA human leucocyte antigen, Anti-TNF anti-tumour necrosis factor drug, sDMARD synthetic disease modifying anti-rheumatic drug
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Men had significantly lower MMP-3 concentrations
than women (adjusted odds ratio, ORadj 0.91; 95% CI
0.83, 0.99; p < 0.0001). MMP-3 was associated with
hsCRP in patients with PsSpA, pPsA and AS. In
patients with AS, the ASDAS was positively associ-
ated with Dkk-1 (ß 0.07; p = 0.003), M-CSF (ß 0.87;
p = 0.001), and MMP-3 (ß 0.001; p = 0.05), and nega-
tively associated with OPG (ß − 1.66; p = 0.03). In pa-
tients with PsSpA, the ASDAS was positively
associated with M-CSF (ß 0.61; p = 0.05) only.
ASDAS was included in regression models comparing
concentrations in the arthritis groups, to adjust for
axial disease activity as a potential confounder, ac-
knowledging that peripheral arthritis is also some-
what captured by the ASDAS. Anti-TNF use did not
appear to influence the concentrations of these four
biomarkers in this cross-sectional analysis.
Biomarker concentrations in HC compared with each
disease group
On multinomial logistic regression, Dkk-1 concentra-
tions were significantly lower in patients with PsC com-
pared with HC (ORadj 0.72 per ng/mL increase in
concentration; 95% CI 0.61, 0.86; p = 2 × 10−4) (Table 2).
M-CSF concentrations were significantly lower in pa-
tients with pPsA (ORadj 0.14 per ng/mL increase; 95% CI
0.06, 0.32; p < 1 × 10−5), PsSpA (ORadj 0.07 per ng/ml in-
crease; 95% CI 0.03, 0.17; p < 1 × 10−8), and AS (ORadj
0.37 per ng/mL increase; 95% CI 0.16, 0.85; p < 1 × 10−7)
compared with HC. MMP-3 concentrations were signifi-
cantly higher patients with in pPsA (ORadj 1.06 per ng/
mL increase; 95% CI 1.01, 1.10; p = 0.02), PsSpA (ORadj
1.06 per ng/mL increase; 95% CI 1.01, 1.11; p = 0.02),
and AS (ORadj 1.06 per ng/mL increase; 95% CI 1.01,
1.11; p = 0.01) compared with HC. OPG concentrations
Table 2 Serum bone biomarker concentrations in disease groups compared with the reference healthy control group
Group Serum concentration ng/mL
Median (IQR)
Adjusted odds ratio*
(per ng/mL increase in concentration)
95% CI p value
Dkk-1 (^Homogeneity p value = 0.08)
HC 3.52 (2.72, 4.46)
PsC 2.50 (1.87, 3.42) 0.72 0.61, 0.86 2 × 10−4
pPsA 3.03 (1.93, 3.69) 0.88 0.74, 1.04 0.14
PsSpA 3.34 (2.43, 4.44) 1.00 0.87, 1.15 0.99
AS 3.51 (2.92, 4.58) 1.10 0.97, 1.25 0.13
M-CSF (^Homogeneity p value = 0.26)
HC 0.81 (0.41, 0.99)
PsC 0.62 (0.25, 0.88) 0.59 0.32, 1.08 0.09
pPsA 0.29 (0.16, 0.68) 0.14 0.06, 0.32 <1 × 10−5
PsSpA 0.27 (0.17, 0.64) 0.07 0.03, 0.17 <1 × 10−8
AS 0.32 (0.17, 0.58) 0.37 0.16, 0.85 <1 × 10−7
MMP-3 (^Homogeneity p value = 4 × 10−4)
HC 16.67 (9.74, 20.64)
PsC 13.13 (9.52, 18.37) 1.05 1.00, 1.09 0.06
pPsA 16.54 (11.77, 26.84) 1.06 1.01, 1.10 0.02
PsSpA 19.83 (11.32, 29.60) 1.06 1.01, 1.11 0.02
AS 19.73 (14.90, 28.02) 1.06 1.01, 1.11 0.01
OPG (^Homogeneity p value = 5 × 10−8)
HC 0.153 (0.116, 0.173)
PsC 0.165 (0.130, 0.211) 8.80 0.25, 309.42 0.23
pPsA 0.190 (0.118, 0.285) 25.77 0.72, 913.42 0.07
PsSpA 0.165 (0.121, 0.244) 8.72 0.23, 334.50 0.24
AS 0.165 (0.102, 0.221) 4.78 0.12, 198.22 0.41
95% CI 95% confidence interval, AS ankylosing spondylitis, HC healthy control, PsC psoriasis without arthritis, pPsA peripheral-only PsA,
PsSpA psoriatic spondyloarthropathy, Dkk-1 Dickkopf 1, MMP-3 matrix metalloproteinase 3, M-CSF macrophage colony stimulating factor, OPG osteoprotegerin
n = 143 AS, 41 HC, 108 pPsA, 194 PsC, 117 PsSpA
^Multinomial logistic regression: homogeneity p value tests for no difference in the concentration of each biomarker across all five groups
(adjusted for sex, age at blood sampling, and the other biomarkers)
*Multinomial logistic regression comparing HC with each of the 4 disease groups (adjusted for sex, age at blood sampling, and other biomarkers)
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were statistically no different in HC compared with any
disease group. The test for homogeneity was used to de-
termine whether biomarkers had significantly different
effects when disease groups were modelled separately,
whilst controlling for sex, age, and other biomarkers.
MMP-3 (homogeneity p = 4 × 10−4) and OPG (homogen-
eity p = 5 × 10−8) concentrations were significantly differ-
ent across the five groups (Table 2). Taken together,
these analyses indicate that Dkk-1, M-CSF, and MMP-3
have different concentrations in healthy controls
compared with disease groups, and therefore may be
biomarkers of pathology.
Biomarkers of disease phenotypes
Biomarkers of arthritis in patients with psoriasis
Biomarker concentrations were compared in patients with
psoriasis with (PsA; n = 244) and without (PsC; n = 200)
inflammatory arthritis. MMP-3 concentrations were
significantly higher in patients with PsA (median
17.44 ng/mL; IQR 11.79, 26.88) compared with PsC (me-
dian 13.13 ng/mL; IQR 9.52, 18.37) (ORadj 1.02 per ng/mL
increase; 95% CI 1.01, 1.03; p = 0.0004) (Table 3). Patients
with PsA (median 0.28 ng/mL; IQR 0.16, 0.67) had signifi-
cantly lower M-CSF concentrations than PsC (median
0.62 ng/mL; IQR 0.25, 0.88) (ORadj 0.44 per ng/mL in-
crease in PsA vs. PsC; 95% CI 0.24, 0.82; p = 0.01).
Biomarkers of radiographic axial disease
Biomarker concentrations were compared in patients with
arthritis with radiographic axial disease (RAD; n = 274;
117 PsSpA and 157 AS) and without RAD (non-RAD;
n = 127 pPsA). Dkk-1 concentrations were significantly
higher in RAD (median 3.42 ng/mL; IQR 2.75, 4.49)
compared with non-RAD (median 3.03 ng/mL; IQR
1.93, 3.69) cases (ORadj 1.22 per ng/mL increase; 95%
CI 1.05, 1.42; p = 0.01) (Table 3). OPG concentrations
Table 3 Serum bone biomarker concentrations compared between disease groups
Unadjusted Adjusted
Odds ratio per ng/mL
increase in concentration
95% CI p value odds ratio per ng/mL
increase in concentration
95% CI p value
PsA vs. PsC cases
Dkk-1 1.16 1.03, 1.32 0.02 1.14* 0.99, 1.31 0.07
M-CSF 0.23 0.13, 0.39 <1 × 10−7 0.44* 0.24, 0.82 0.01
MMP-3 1.01 1.00, 1.03 0.03 1.02* 1.01, 1.03 4 × 10−4
OPG 2.36 0.80, 6.92 0.12 2.51* 0.68, 9.28 0.17
RAD vs. non-RAD cases
Dkk-1 1.23 1.06, 1.44 0.01 1.22** 1.05, 1.42 0.01
M-CSF 0.60 0.31, 1.17 0.13 0.64** 0.32, 1.26 0.19
MMP-3 1.01 1.00, 1.02 0.20 1.00** 1.00, 1.01 0.30
OPG 0.17 0.05, 0.62 0.01 0.20** 0.05, 0.80 0.02
AS vs. PsSpA cases
Dkk-1 1.15 1.01, 1.30 0.04 1.18**** 1.02, 1.35 0.02
M-CSF 1.16 0.50, 2.78 0.72 1.28**** 0.52, 3.22 0.59
MMP-3 1.00 1.00, 1.01 0.24 1.00**** 1.00, 1.01 0.17
OPG 0.22 0.03, 1.54 0.13 0.31**** 0.04, 2.27 0.25
PsSpA vs. pPsA cases
Dkk-1 1.08 0.95, 1.23 0.26 1.06*** 0.95, 1.19 0.28
M-CSF 0.55 0.25, 1.21 0.14 0.50*** 0.22, 1.11 0.09
MMP-3 1.01 0.99, 1.02 0.31 1.00*** 0.99, 1.02 0.73
OPG 0.30 0.08, 1.15 0.08 0.28*** 0.06, 1.18 0.08
All models were adjusted potentially for sex, age, disease duration, anti-TNF use, and where appropriate psoriasis, Ankylosing Spondylitis Disease Severity Score
(ASDAS), body mass index and RAD)
PsSpA psoriatic spondyloarthritis (n = 118), PsA psoriatic arthritis (n = 201), pPsA peripheral-only PsA (n = 127), AS ankylosing spondylitis (n = 157), RAD radiographic
axial disease (n = 274), Dkk-1 Dickkopf 1, OPG osteoprotegerin, MMP-3 matrix metalloproteinase 3, M-CSF macrophage colony stimulating factor, 95% CI 95%
confidence interval
*Multivariable logistic regression (reduced model adjusted for age, disease duration, and the Psoriatic Arthritis Spondylitis Radiology Index
**Multivariable logistic regression (reduced model adjusted for sex, age, and disease duration)
***Multivariable logistic regression (reduced model adjusted for the ASDAS)
****Multivariable logistic regression (reduced model adjusted for sex, age, and disease duration)
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were significantly lower in patients with RAD (median
0.16 ng/mL; IQR 0.11, 0.22) compared with non-RAD
(median 0.19 ng/mL; IQR 0.12, 0.28) (ORadj 0.20 per
ng/mL increase; 95% CI 0.05, 0.80; p = 0.02). Skin
psoriasis was not a significant covariable.
Biomarkers were tested along a spectrum of increasing
RAD. Patients with AS had significantly higher Dkk-1
concentrations than those with PsSpA (ORadj 1.18 per
ng/mL increase; 95% CI 1.02, 1.35; p = 0.02) (Table 3).
Biomarker concentrations were statistically no different
in patients with PsSpA and patients with pPsA.
Association of phenotype with a biomarker panel
Multivariable logistic regression was performed to de-
termine whether a combination (panel) of bone bio-
markers and hsCRP, excluding clinical covariables,
might have a stronger association with disease pheno-
type. A number of different panels were tested. The
panel comprising Dkk-1 (ORadj 0.09 per ng/mL in-
crease; 95% CI 0.03, 0.23; p = 4 × 10−7), MMP-3 (ORadj
1.07 per ng/mL increase; 95% CI 1.02, 1.12; p = 0.002)
and OPG (ORadj 31.00 per ng/mL increase; 95% CI
0.66, 1451.86; p = 0.08) was best able to differentiate
patients with PsA from HC, with an area under the re-
ceiver operating characteristic (ROC) curve (AUC) of
0.84. The AUC was < 0.73 for other all other biomarker
panels as determinants of phenotype (PsA vs. PsC, PsC
vs. HC, RAD vs. non-RAD, PsSpA vs. pPsA, and PsSpA
vs. AS).
Biomarkers of radiographic axial disease severity and
morphology
Using multivariable generalised additive models, no bio-
marker was associated with RAD severity (as measured
by the mSASSS and PASRI) or morphology (as mea-
sured by the osteoproliferation subdomain of the PASRI,
which scores for vertebral corner sclerosis, vertebral syn-
desmophyte formation, and cervical facet joint fusion) in
either PsSpA or AS. In patients with PsSpA only, Dkk-1
concentrations were significantly lower in patients with
a PASRI erosion score ≥ 1 (ORadj 0.28 per ng/mL
increase; 95% CI 0.10, 0.80; p = 0.02) than in those
without erosions.
Biomarker concentration thresholds differentiating
disease groups
ROC analyses were performed to determine whether
MMP-3 and M-CSF concentration thresholds could use-
fully differentiate patients with PsA from HC. In a model
of maximum accuracy (proportion of cases correctly
classified), an MMP-3 threshold of 7.21 ng/mL had sen-
sitivity of 0.99 and specificity of 0.12 (AUC 0.66; 95% CI
0.59, 0.74), and an M-CSF threshold of 0.02 ng/mL had
sensitivity of 1.00 and specificity of 0.00 (AUC 0.24; 95%
CI 0.17, 0.31) (Table 4).
Similarly, ROC analyses were used to determine
whether MMP-3 and M-CSF concentration thresholds
could usefully differentiate PsA from PsC. In a model of
maximum accuracy an MMP-3 threshold of 14.51 ng/mL
had sensitivity of 0.76 and specificity of 0.60 (AUC 0.70;
95% CI 0.65, 0.75); and an M-CSF threshold of 0.05 ng/ml
had sensitivity of 0.99 and specificity of 0.01 (AUC 0.34;
95% CI 0.29, 0.40). The effect of mandating sensitivity
of > 0.95, possibly at the expense of specificity, is shown
in Table 4.
Since in patients with PsA (n = 200), Dkk-1 concentra-
tions were higher and OPG concentrations were lower in
patients with with RAD compared to those without RAD,
biomarker concentration thresholds could potentially be
used to identify patients with PsA for spinal imaging. In a
model of maximum accuracy, a Dkk-1 threshold of
4.96 ng/mL had sensitivity of 0.15 and specificity of 0.94
(AUC 0.56; 95% CI 0.44, 0.67); and an OPG threshold of
3.88 ng/ml had sensitivity of 0.00 and specificity of 0.99
(AUC 0.47; 95% CI 0.39, 0.56) (Table 4). The effect of
mandating sensitivity of > 0.95, possibly at the expense of
specificity, is shown in Table 4.
Discussion
We have previously reported a study of the same cohort,
showing clinical, imaging, and genetic signatures unique
to pPsA, PsSpA, and AS [2]. Using the same large cohort
of well-characterised cases and matched healthy con-
trols, we sought to determine whether there are unique
serum-soluble bone-turnover biomarker signatures.
Previously reported studies that have investigated PsA in
terms of serum bone biomarkers have been limited by
small sample size, variable endpoints, and heterogenous
laboratory methods [1].
MMP-3 and M-CSF appear to be biomarkers of arth-
ritis, differentiating patients with PsA from those with
PsC, and patients with SpA from HC. Hence, MMP-3
and M-CSF concentration thresholds may be useful to
screen for PsA in patients with PsC. We have presented
two such models, allowing the clinician to choose
whether very high sensitivity at the expense of specificity
is most important in their setting (model with ≥ 0.95
sensitivity), or a more equitable balance between sensi-
tivity and specificity is required (model of maximum ac-
curacy). Neither MMP-3 nor M-CSF differentiated
various forms of SpA, i.e. pPsA, PsSpA and AS, implying
they may share a common pathological pathway, e.g.
entheseal disease or bone resorption. Other studies have
shown MMP-3 levels to be four times higher in synovial
fluid compared with serum in patients with AS with per-
ipheral involvement [11], and a thousand times higher in
synovial tissue compared with serum in patients with
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SpA with peripheral involvement [12]. MMP-3 levels are
higher in patients with axial SpA with peripheral arth-
ritis rather than without [12–14]. MMP-3 may therefore
be a biomarker more specific to peripheral synovial-
based arthritis, than to axial non-synovial entheseal-
based arthritis. MMP-3 and M-CSF need further testing
to determine their performance in differentiating PsA
from rheumatoid arthritis (RA) and inflammatory osteo-
arthritis of the interphalangeal joints.
Dkk-1 appears to be a biomarker of axial disease in
SpA, with a pattern for increasing concentration along a
spectrum of increasing axial arthritis. Dkk-1 could be used
to differentiate patients with PsA with and without
axial arthritis, and patients with PsSpA from those with
AS. Our previous research has shown that 25% of pa-
tients with PsA with radiographic axial disease do not
recall ever having inflammatory axial symptoms [2].
Dkk-1 and OPG testing may therefore offer an oppor-
tunity to identify “symptomatically-silent” axial disease
in PsA. We have therefore proposed Dkk-1 concentra-
tion thresholds that might be used to screen for axial
disease in patients with PsA. Similarly, OPG appears to
be a biomarker of axial disease in patients with SpA, and
could be used to differentiate patients with axial SpA
from peripheral-only SpA, independently of psoriasis
status.
Since Dkk-1 is an inhibitor of the Wnt pathway, which
normally induces osteoblastogenesis and new bone for-
mation, one might expect Dkk-1 concentrations to be
progressively lower along a spectrum of diseases with in-
creasing new bone formation. However, consistent with
most other studies, Dkk-1 concentrations were higher in
patients with AS compared with HC [15–17]; no differ-
ent in patients with pPsA compared with HC [15]; and
higher in patients with AS compared with PsA [15].
Dkk-1 levels may be higher in SpA, particularly AS, be-
cause Dkk-1 is pathologically dysfunctional. Daoussis
et al. found that whilst serum total Dkk-1 levels are
higher in patients with AS compared with HC or pa-
tients with PsA, Dkk-1 is dysfunctional in AS; Dkk-1
binds less avidly to its receptor LRP6, has an abnormal
stimulatory effect on the Wnt pathway, and responds ab-
normally to anti-Dkk-1 monoclonal antibodies [15].
Yucong et al. also reported less avid binding of Dkk-1 to
its receptor in patients with AS compared with HC [18].
These studies explain the progressively higher Dkk-1
Table 4 Biomarker concentration thresholds differentiating disease groups, using receiver operating characteristic analyses
Maximum accuracy
(proportion of cases correctly classified)
Minimum value for
sensitivity≥ 0.95
PsC vs. PsA HC vs. PsA PsC vs. PsA HC vs. PsA
MMP-3
Threshold (ng/mL) 14.51 7.21 8.22 8.32
Sensitivity 0.76 0.99 0.96 0.95
Specificity 0.60 0.12 0.16 0.20
AUC (95% CI) 0.70 (0.65, 0.75) 0.66 (0.59, 0.74) 0.70 (0.65, 0.75) 0.66 (0.59, 0.74)
M-CSF
Threshold (ng/mL) 0.05 0.02 0.10 0.02
Sensitivity 0.99 1.00 0.95 1.00
Specificity 0.01 0.00 0.02 0.00
AUC (95% CI) 0.34 (0.29, 0.40) 0.24 (0.17, 0.31) 0.34 (0.29, 0.40) 0.24 (0.17, 0.31)
PsA cases: Non-RAD vs. RAD PsA cases: Non-RAD vs. RAD
Dkk-1
Threshold (ng/mL) 4.96 0.91
Sensitivity 0.15 0.96
Specificity 0.94 0.05
AUC (95% CI) 0.56 (0.44, 0.67) 0.56 (0.44, 0.67)
OPG
Threshold (ng/mL) 3.88 0.08
Sensitivity 0.00 0.95
Specificity 0.99 0.08
AUC (95% CI) 0.47 (0.39, 0.56) 0.47 (0.39, 0.56)
AUC area under the curve, 95CI 95% confidence interval, Dkk-1 Dickkopf 1, M-CSF Macrophage colony stimulating factor, MMP-3 Matrix metalloproteinase 3,
OPG osteoprotegerin, PsA psoriatic arthritis, PsC psoriasis without arthritis, HC healthy control, RAD radiographic axial disease
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concentrations along our spectrum of patients with in-
creasing RAD, as an attempt to compensate for dysfunc-
tional Dkk-1. Dysfunctional Dkk-1 is inadequately
inhibiting Wnt-pathways, allowing unimpeded bone for-
mation, possibly translating to the osteoproliferative
phenotype of SpA.
We found lower Dkk-1 concentrations in patients with
PsSpA with vertebral erosions. In human embryonic
stems cells, Dkk-1 plays an important role promoting
synovial angiogenesis, that might encourage inflamma-
tory pannus formation, and subsequent erosion [19].
There is emerging evidence that Wnt-pathways are in-
volved in non-bone pathways associated with psoriasis,
characterised by keratinocyte hyperproliferation and al-
tered innate immunity [20–25].
In SpA there is a paradox of osteoproliferation and
bone resorption. Patients with AS [26–28] or PsA [29]
are prone to osteoporosis. As OPG inhibits bone resorp-
tion, low OPG levels may translate to low bone mineral
density. However, as we did not measure bone mineral
density, we cannot determine if these serum biomarkers
are reflecting SpA-related pathology in trabecular bone,
or vertebral corners and sacroiliac joints. The measure-
ment of these bone markers in tissues sampled from the
vertebral corners and sacroiliac joints would be mechan-
istically more informative. However, obtaining such sam-
ples in live participants would be procedurally
challenging, painful for participants, and likely hamper
study enrolment. Our study would have been further
strengthened had we measured serum RANKL levels, as
there is some evidence that the ratio of RANKL:OPG is
more indicative of axis dysregulation than either bio-
marker alone [30–33].
Further research is needed to determine whether
synthetic and biological DMARDs directly alter bone
biomarkers, independently of their influence on
disease activity. Within the constraints of our cross-
sectional study design, we demonstrated no relation-
ship between anti-TNF use and levels of biomarkers.
However, other studies have shown that biomarker
concentrations are influenced by anti-TNF use, longi-
tudinally in PsA [34, 35], cross-sectionally [32, 36] and
longitudinally [11, 17, 37–40] in AS, in AS clinical
responders and non-responders [38], only in AS
patients with peripheral arthritis [41], and with differ-
ential direction of change (Dkk-1) in AS compared
with RA [15].
The reliability of our results is strengthened by the
large sample size, robust case classification, no missing
data for three biomarkers, matching of HCs with PsA
cases, and multivariable regression modelling allowing
adjustment for confounders, particularly disease
duration and activity. Our results are generalisable to
real-world clinical practice, because consecutive
unselected clinic attendees were invited to participate,
reducing selection bias, and enrolling patients of differ-
ing ages, stages of disease, and disease activity.
Our results would have been strengthened had reliable
commercially available kits been available to measure
active-MMP-3 rather than total MMP-3 [42–45], func-
tional Dkk-1 or Dkk-1 biological activity rather than total
Dkk-1 [15, 18, 46], RANK ligand [30–33], sclerostin, and
neoepitopes of type 2 collagen metabolism (CPII and
C2C). The cross-sectional design of our study reduced the
ability to entirely adjust for time-varying variables such as
disease activity, medication use and BMI, and unmeasured
confounders known to alter OPG and MMP-3 concentra-
tions [10, 47, 48]. However, the direction and magnitude
of their confounding is unlikely to be significantly different
across the four disease groups. We acknowledge that
some patients with pPsA will have non-radiographic
PsSpA, perhaps better detected on magnetic resonance
imaging (MRI) or computed tomography (CT).
Conclusions
This study gives further insight into the pathophysiology
of psoriasis, PsA, and AS. These bone biomarkers offer
potential to screen for PsA in psoriasis cohorts, screen for
axial arthritis in PsA, and help differentiate PsSpA from
AS. A larger study is underway by our group to replicate
these findings in an independent well-characterised incep-
tion cohort. These four markers will also be investigated
longitudinally as biomarkers of disease activity, treatment
response, and prognosis.
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